This novel mechanism of action is designed to support safer and more predictable bone formation compared to commercially available bone growth factors. Finally, they needed a solution they could get up and running quickly and Performio’s fast implementation timeframe met their needs. It is the first bone graft to be approved for use in the cervical spine and only the second PMA-approved bone graft in the spine backed by Level 1 human clinical data. In addition, they liked the modern UI, interactive dashboards, reporting capabilities, and the ability to make plan adjustments easily. The SolutionĪfter evaluating other solutions on the market, Performio stood out because it could handle the complexity of their override rules. They knew they needed a better way to track override rules and provide better visibility of commissions both for their finance team and for their distributors.
#MECHANISM OF ACTOION FOR IFACTOR BONE GRAFT MANUAL#
Unfortunately the override rules added too much complexity and resulted in a manual commissions process.
The accounting team would spend multiple days each month trying to apply override rules for commissions. The handling characteristics of i-FACTOR Putty allow it to. This novel mechanism of action enhances the bodys natural bone healing process resulting in safe, predictable bone formation. The ChallengeĬerapedics pays 45% of their annual revenue in commissions payouts. PMA approved as a bone graft substitute for dental indications, with study outcomes proving clinical superiority to both alloplasts and allografts (DBM). This novel mechanism of action is designed to support safer and more. This novel mechanism of action is designed to support safer and more predictable bone formation compared to commercially available bone growth factors. CAUTION: In the United States, i-FACTOR Peptide Enhanced Bone Graft is indicated. According to the company, i-Factor is the only biologic bone graft that combines the small P-15 peptide with anorganic bone mineral (ABM). i-FACTOR Peptide Enhanced Bone Graft is the only biologic bone graft in orthopedics that incorporates a small peptide as an attachment factor to stimulate the natural bone healing process. Next-Generation Synthetic Bone Grafts Advancements in biomaterials have resulted in the development of next-generation synthetic bone graft products, different from Bioglass, that play an active role in the bone formation process. Aboutįounded in 2000, Cerapedics is an ortho- biologics company focused on developing and commercializing its proprietary small peptide (P-15) technology platform. Only i-Factor® bone graft utilizes P-15 cell binding peptide to attract osteogen. The handling characteristics of i-FACTOR™ Putty allow it to be used in contained implants such as spinal interbody fusion devices.Cerapedics Streamlines Commissions for Large Distributor Network with Performio. Watch this short video to learn about i-FACTORs unique mechanism of action. This novel mechanism of action enhances the body's natural bone healing process resulting in safe, predictable bone formation. I-FACTOR™ Putty combines a unique anorganic bone mineral (ABM) and small peptide (P-15™) that acts as an attachment factor for specific integrins on osteogenic cells. Two product forms (Putty and Flex) allow clinicians to choose the handling characteristics best suited to specific applications. I-FACTOR™ bone graft is easy to use in a wide range of orthopedic and spine procedures.
I-FACTOR™ demonstrates efficacy equivalent to autograft. PMA approved as a bone graft substitute for dental indications, with study outcomes proving clinical superiority to both alloplasts and allografts (DBM). This combination provides a proven osteoconductive scaffold with an abundance of P-15 attachment. i-FACTOR Peptide Enhanced Bone Graft is the only biologic bone graft in orthopedics that incorporates a small peptide as an attachment factor to stimulate the. i-FACTOR Bone Graft combines a synthetic version of this peptide, known as P-15, with a hydroxyapatite, anorganic bone mineral (ABM). I-FACTOR™ has been used in more than 2,000 spine and trauma surgeries worldwide. This protein segment is responsible for the attachment and proliferation of osteogenic cells that produce bone. Unlike growth factor products, i-FACTOR™ only stimulates bone growth in the presence of bone forming cells, decreasing the likelihood of ectopic bone formation. I-FACTOR™ targets specific integrins in osteogenic cells to stimulate the natural bone healing process. i-FACTOR Peptide Enhanced Bone Graft (P-15/ABM) is only the second FDA PMA approved bone graft on the market, and it its novel mechanism of action. I-FACTOR™ Biologic Bone Graft enables surgeons to avoid the morbidity of harvesting autograft.
0 kommentar(er)
